{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:19:41Z","timestamp":1792091981359,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["No. 20202BABL206161"],"award-info":[{"award-number":["No. 20202BABL206161"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["No. 20212BAG70003"],"award-info":[{"award-number":["No. 20212BAG70003"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019227","name":"Foundation of Jiangxi Educational Commission","doi-asserted-by":"publisher","award":["No. GJJ218913"],"award-info":[{"award-number":["No. GJJ218913"]}],"id":[{"id":"10.13039\/501100019227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020205","name":"Health Commission of Jiangxi Province","doi-asserted-by":"publisher","award":["No. 202310853"],"award-info":[{"award-number":["No. 202310853"]}],"id":[{"id":"10.13039\/501100020205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020205","name":"Health Commission of Jiangxi Province","doi-asserted-by":"publisher","award":["No. 202210015"],"award-info":[{"award-number":["No. 202210015"]}],"id":[{"id":"10.13039\/501100020205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020205","name":"Health Commission of Jiangxi Province","doi-asserted-by":"publisher","award":["No. 20203789"],"award-info":[{"award-number":["No. 20203789"]}],"id":[{"id":"10.13039\/501100020205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020205","name":"Health Commission of Jiangxi Province","doi-asserted-by":"publisher","award":["No. 202210069"],"award-info":[{"award-number":["No. 202210069"]}],"id":[{"id":"10.13039\/501100020205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Burkitt\u2019s lymphoma, one of the most common subtypes of pediatric malignant lymphoma, is notorious for its swift onset, aggressive proliferation, pronounced invasiveness, and marked malignancy. The therapeutic landscape for Burkitt\u2019s lymphoma currently falls short of providing universally effective and tolerable solutions. Andrographolide, a primary active component of <jats:italic>Andrographis paniculata<\/jats:italic>, is renowned for its properties of heat-clearing, detoxification, inflammation reduction, and pain relief. It is predominantly used in treating bacterial and viral infections of the upper respiratory tract, as well as dysentery. Various reports highlight the antitumor effects of andrographolide. Yet, its specific impact and the underlying mechanism of action on Burkitt\u2019s lymphoma remain an uncharted area of research.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>We employed network pharmacology to pinpoint the targets of andrographolide\u2019s action on Burkitt\u2019s lymphoma and the associated pathways. We then evaluated the impact of andrographolide on Burkitt\u2019s lymphoma using both in vitro and in vivo patient-derived xenograft (PDX) models. Concurrently, we confirmed the molecular targets of andrographolide in Burkitt\u2019s lymphoma through immunofluorescence assays.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>Utilizing network pharmacology, we identified 15 relevant targets, 60 interrelationships between these targets, and numerous associated signaling pathways for andrographolide\u2019s action on Burkitt\u2019s lymphoma. In vitro efficacy tests using High-throughput Drug Sensitivity Testing and in vivo PDX model evaluations revealed that andrographolide effectively curtailed the growth of Burkitt\u2019s lymphoma. Moreover, we observed a increased in the expression of JUN (c-Jun) and CASP3 (Caspase 3) proteins in Burkitt\u2019s lymphoma cells treated with andrographolide.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Andrographolide inhibits the growth of Burkitt\u2019s lymphoma by inhibiting JUN and CASP3 proteins.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00280-023-04626-4","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T18:01:50Z","timestamp":1703613710000},"page":"381-391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Andrographolide inhibits Burkitt\u2019s lymphoma by binding JUN and CASP3 proteins"],"prefix":"10.1007","volume":"93","author":[{"given":"Junquan","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongliang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuangfan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quangang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-7643","authenticated-orcid":false,"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,26]]},"reference":[{"issue":"1","key":"4626_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-022-00404-3","volume":"8","author":"C L\u00f3pez","year":"2022","unstructured":"L\u00f3pez C, Burkhardt B, Chan J, Leoncini L, Mbulaiteye S, Ogwang M et al (2022) Burkitt lymphoma. Nat Rev Dis Prim 8(1):78","journal-title":"Nat Rev Dis Prim"},{"issue":"6","key":"4626_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1182\/blood.2019004099","volume":"137","author":"J Crombie","year":"2021","unstructured":"Crombie J, LaCasce A (2021) The treatment of Burkitt lymphoma in adults. Blood 137(6):743\u2013750","journal-title":"Blood"},{"issue":"20","key":"4626_CR3","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"issue":"12","key":"4626_CR4","first-page":"1397","volume":"60","author":"G Brady","year":"2007","unstructured":"Brady G, MacArthur GJ, Farrell PJ (2007) Epstein\u2013Barr virus and Burkitt lymphoma. J Clin Pathol 60(12):1397\u20131402","journal-title":"J Clin Pathol"},{"issue":"4","key":"4626_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3816\/CLM.2009.n.060","volume":"9","author":"JL Kelly","year":"2009","unstructured":"Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS et al (2009) Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma 9(4):307\u2013310","journal-title":"Clin Lymphoma Myeloma"},{"issue":"12","key":"4626_CR6","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1093\/annonc\/mdt414","volume":"24","author":"AM Evens","year":"2013","unstructured":"Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N et al (2013) A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M\/IVAC regimen for untreated Burkitt\u2019s lymphoma. Ann Oncol 24(12):3076\u20133081","journal-title":"Ann Oncol"},{"issue":"1","key":"4626_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/molecules26010005","volume":"26","author":"RA Burgos","year":"2020","unstructured":"Burgos RA, Alarc\u00f3n P, Quiroga J, Manosalva C, Hancke J (2020) Andrographolide, an anti-inflammatory multitarget drug: all roads lead to cellular metabolism. Molecules 26(1):5","journal-title":"Molecules"},{"issue":"1","key":"4626_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13046-018-0926-9","volume":"37","author":"Y Peng","year":"2018","unstructured":"Peng Y, Wang Y, Tang N, Sun D, Lan Y, Yu Z et al (2018) Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res CR 37(1):248","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"20","key":"4626_CR9","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.1021\/acs.jafc.8b00810","volume":"66","author":"M Yuan","year":"2018","unstructured":"Yuan M, Meng W, Liao W, Lian S (2018) Andrographolide antagonizes TNF-\u03b1-induced IL-8 via inhibition of NADPH oxidase\/ROS\/NF-\u03baB and Src\/MAPKs\/AP-1 axis in human colorectal cancer HCT116 cells. J Agric Food Chem 66(20):5139\u20135148","journal-title":"J Agric Food Chem"},{"issue":"8","key":"4626_CR10","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1177\/1947601910383416","volume":"1","author":"JY Chun","year":"2010","unstructured":"Chun JY, Tummala R, Nadiminty N, Lou W, Liu C, Yang J et al (2010) Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. Genes Cancer 1(8):868\u2013876","journal-title":"Genes Cancer"},{"issue":"1","key":"4626_CR11","doi-asserted-by":"publisher","first-page":"7924","DOI":"10.1038\/s41598-018-26278-8","volume":"8","author":"S Reabroi","year":"2018","unstructured":"Reabroi S, Saeeng R, Boonmuen N, Kasemsuk T, Saengsawang W, Suksen K et al (2018) The anti-cancer activity of an andrographolide analogue functions through a GSK-3\u03b2-independent Wnt\/\u03b2-catenin signaling pathway in colorectal cancer cells. Sci Rep 8(1):7924","journal-title":"Sci Rep"},{"key":"4626_CR12","first-page":"1","volume":"25","author":"Y He","year":"2023","unstructured":"He Y, Mei J, Hao H, Liu F, Yi Y, Hu C et al (2023) Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer. J Cancer Res Clin Oncol 25:1\u201311","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"4626_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrc818","volume":"2","author":"PK Vogt","year":"2002","unstructured":"Vogt PK (2002) Fortuitous convergences: the beginnings of JUN. Nat Rev Cancer 2(6):465\u2013469","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"4626_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1101\/gad.13.5.607","volume":"13","author":"M Schreiber","year":"1999","unstructured":"Schreiber M, Kolbus A, Piu F, Szabowski A, M\u00f6hle-Steinlein U, Tian J et al (1999) Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 13(5):607\u2013619","journal-title":"Genes Dev"},{"issue":"1","key":"4626_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/emboj\/18.1.188","volume":"18","author":"R Wisdom","year":"1999","unstructured":"Wisdom R, Johnson RS, Moore C (1999) c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. Embo J 18(1):188\u2013197","journal-title":"Embo J"},{"issue":"3","key":"4626_CR16","first-page":"870","volume":"10","author":"L Zhang","year":"2020","unstructured":"Zhang L, Sun S, Wang Y, Mo Y, Xiong F, Zhang S et al (2020) Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway. Am J Cancer Res 10(3):870\u2013883","journal-title":"Am J Cancer Res"},{"issue":"6","key":"4626_CR17","first-page":"1417","volume":"56","author":"S Wang","year":"2020","unstructured":"Wang S, Li H, Chen S, Wang Z, Yao Y, Chen T et al (2020) Andrographolide induces apoptosis in human osteosarcoma cells via the ROS\/JNK pathway. Int J Oncol 56(6):1417\u20131428","journal-title":"Int J Oncol"},{"issue":"19","key":"4626_CR18","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1158\/1078-0432.CCR-10-0883","volume":"16","author":"S Yang","year":"2010","unstructured":"Yang S, Evens AM, Prachand S, Singh AT, Bhalla S, David K et al (2010) Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata. Clin Cancer Res 16(19):4755\u20134768","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4626_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.immuni.2016.01.020","volume":"44","author":"L Galluzzi","year":"2016","unstructured":"Galluzzi L, L\u00f3pez-Soto A, Kumar S, Kroemer G (2016) Caspases connect cell-death signaling to organismal homeostasis. Immunity 44(2):221\u2013231","journal-title":"Immunity"},{"issue":"4","key":"4626_CR20","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ijc.31374","volume":"143","author":"M Zhou","year":"2018","unstructured":"Zhou M, Liu X, Li Z, Huang Q, Li F, Li CY (2018) Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells. Int J Cancer 143(4):921\u2013930","journal-title":"Int J Cancer"},{"issue":"8","key":"4626_CR21","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/ijc.32662","volume":"146","author":"J Shi","year":"2020","unstructured":"Shi J, Li Y, Jia R, Fan X (2020) The fidelity of cancer cells in PDX models: characteristics, mechanism and clinical significance. Int J Cancer 146(8):2078\u20132088","journal-title":"Int J Cancer"},{"issue":"2","key":"4626_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.14348\/molcells.2016.2350","volume":"39","author":"SY Cho","year":"2016","unstructured":"Cho SY, Kang W, Han JY, Min S, Kang J, Lee A et al (2016) An integrative approach to precision cancer medicine using patient-derived xenografts. Mol Cells 39(2):77\u201386","journal-title":"Mol Cells"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04626-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04626-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04626-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T15:04:56Z","timestamp":1710860696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04626-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["4626"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04626-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,26]]},"assertion":[{"value":"12 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}